GlucoLight Corporation
Medical Devices & Tech  Advamed Member
2426 Emrick Boulevard
Bethlehem, PA 18020 USA
phone: 484 893 5132
fax: 484 893 5131
Symbol private
Exchange
Founded 2003
Employees 15
www.glucolight.com
Research Sector Medical Devices & Tech
Summary Description
Medical device company developing continuous, non-invasive glucose sensor for acute care and ambulatory diabetes market.
Management
Ray Krauss, Founder / CEO; Matt Schurman, Ph.D., Founder / CTO; Phil Wallace, COO; Robert G Wilkins MBChB FRCA, VP Medical Affairs & Business Development
Ownership
Financials


* numbers in thousands

 
Keywords
Diabetes, blood sugar, diabetic, metabolic, insulin, photonic, device, noninvasive, tomography, light, optics, photon, adv2007, endocrine, advamed, j2008

Comment | Printable Version | Aug. 27, 2008
If you work for GlucoLight Corporation and want to update this profile, click here


Description
GlucoLight Corporation is addressing the need for continuous non-invasive bedside glucose monitoring in the hospital environment. The company's development and clinical testing of an accurate non-invasive continuous glucose monitor is progressing quickly, with pivotal FDA trials expected in late 2008. Successful commercialization of GlucoLight's technology will enable the implementation of tight glycemic control in the post-surgical environment, which has been shown to reduce patient mortality and morbidity and ultimately save lives. Following market launch of the hospital monitor, GlucoLight plans to miniaturize the device and address the consumer market.
Products / Services
The GlucoLight SENTRIS-100 system will offer the following features, which will meet critical needs: Continuous glucose measurement with a rate of change and direction of change indication; non-invasive acquisition of data, permitting use in the critical post-ICU days when the patient is in a step-down unit, arterial lines have been removed and invasive technologies are impractical; minimal or no lag time between changes in serum glucose and measured glucose accuracy within established criteria across the physiologic range, rapid calibration time; simple calibration procedure requiring only single point initial calibration for rapid display of useful data; lower cost of disposables than current testing methods; substantial savings in nursing time.
Technology / Differentiation
GlucoLight's OCT technology is a novel and original approach to optical glucose measurement that utilizes Optical Coherence Tomography (OCT). This device is non-invasive and therefore painless to use. The SENTRIS-100 glucose monitor is capable of continuous measurement enabling hospitals to more tightly monitor glucose levels in acutely ill patients. Seven pilot studies (2004 - 2007) on healthy volunteer subjects and Type 1 & 2 diabetic subjects have demonstrated the viability of GlucoLight's technology. The first phase of a clinical study on post cardiac surgery patients has been completed. Data analysis shows that the raw glucose signal is accessible during hypotension, edema and infusion of potent vasoactive drugs.
Status
To date, GlucoLight has completed 7 pilot studies of SENTRIS-100, including animal studies, studies on volunteer patients, and, most recently, a study in the intended field of use with post-cardiac surgery patients. GlucoLight's continuous, non-invasive blood glucose monitor requires regulatory clearance, and is not yet commercially available.


2008-10-11-1211